Immunosuppression and ICU-acquired MDROs in critically ill adults
Official title: Impact of Immunosuppression on Intensive Care Unit-acquired Multidrug-resistant Bacteria: a Prospective Multicenter Study in Europe
Run by University Hospital, Lille · NCT06652126 · Data updated 2026-11-12
This study tests how often ICU patients who are immunocompromised acquire or carry resistant bacteria, and how this relates to infections and outcomes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | University Hospital, Lille Academic / other |
| Drugs / interventions | prednisone |
| Locations | 1 site (Lille) |
| Status | Recruiting |
| Started | March 19, 2025 |
| Main results expected | December 1, 2029 |
| Study ends | December 1, 2029 |
| Registry record updated | October 21, 2026 |
| Trial ID | NCT06652126 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18 years and older admitted to the ICU with anticipated stay > 48 hours, including both immunocompromised and immunocompetent patients.
✕Probably not a fit
Patients not at risk for ICU-acquired infections or those with very short ICU stays may be less likely to benefit from the study insights.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational, multicenter study in ICUs focusing on ICU-acquired multidrug-resistant bacteria in adults, including both immunocompetent and immunocompromised patients. The project collects microbiological data to track colonization and infections by resistant pathogens after at least 48 hours in the ICU. It builds on prior findings that isolation measures may influence cross-transmission in immunocompromised patients. The aim is to characterize the frequency and patterns of ICU-MDR colonization and infection and explore factors associated with transmission. No interventional therapies are tested; the study analyzes real-world data to inform infection control priorities in ICUs.
Why it matters
Potential benefit: If successful, findings could improve infection control practices and reduce ICU stays and mortality related to resistant infections.
How similar studies have gone: Prior multicenter work suggests differential risk of MDR colonization and infection in immunocompromised patients, with some protective effects from isolation measures observed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged 18 and over. 2. Admitted to intensive care and whose length of stay is greater than 48 hours (inclusion is at the 48th hour after admission). 3. Immunocompetent OR immunocompromised patients according to one of the following criteria: 1. Solid cancer under treatment or in remission for less than 5 years (including cancers diagnosed during hospitalization in intensive care); 2. Hematological malignancies under treatment or in remission for less than 5 years (including hematological malignancies diagnosed during hospitalization in intensive care); 3. Neutropenia \< 0.7 G/L for ≥ 7 days; 4. Solid organ transplants; 5. Patients with systemic or transplant pathologies requiring treatment with corticosteroids (prednisone equivalent \> 10 mg/day) or other high-dose immunosuppressants for \> 28 days; 6. Human Immunodeficiency Virus (HIV) infection with CD4+ \<200 μL; 7. Genetic immune deficiency. 4. Patients undergoing invasive mechanical ventilation and/or vasopressive amines. 5. Persons who have given their non-opposition. For patients unable to give their non-opposition, this will be obtained from the trusted support person. The patient will be informed as soon as possible and asked to agree to participate in any further research. 6. Patients affiliated to a social security system. Exclusion Criteria: 1. Minor patients (\< 18 years), 2. Length of stay in intensive care less than 48 hours, 3. Moribund patients. 4. Absence of BMR screening (rectal swab routinely, combined with nasal swab in some centers) within 48 hours of admission. 5. Refusal to participate in the study. 6. Vulnerable and/or susceptible patients according to one of the following criteria: 1. Patients under legal protection (guardianship, curatorship, etc.); 2. Patients in prison; 3. Pregnant or breast-feeding women. 7. Patients without social security coverage. 8. Simultaneous participation in another interventional study that could interfere with the evaluation of primary and secondary endpoints (particularly in the case of participation in an interventional study that could modulate the risk of CAR or BMR-ARI).
Where it's running
-
chu de Lille
Lille, France Recruiting
Study contacts
- Study coordinator: Saad NSEIR, Professor
- Email: saadalla.nseir@chu-lille.fr
- Phone: 33 (0)3 20 44 44 95
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Effects of a caregiver's physical contact on ICU patients
This study tests whether brief physical contact from a patient’s primary caregiver can influence vital signs in adults in intensive care.
-
How illness severity and death risk relate to breathing and limb muscle strength in ICU patients
This project will see if how sick ICU patients are and their risk of dying are linked to the strength of their respiratory and skeletal muscles for adults in the ICU.
-
Evaluating agitation in critically ill patients using remote video monitoring
This study is testing a new way to use remote video monitoring to see if it can help doctors better manage agitation in critically ill patients in the ICU.
-
Measuring heart function using AI-guided techniques by minimally trained operators
This study is testing if a new AI tool can help less experienced staff accurately measure heart function in critically ill ICU patients, so they can better manage their fluid needs.
-
Monitoring glucose levels in critically ill patients
This study looks at how often critically ill patients in the ICU experience low blood sugar and how using continuous glucose monitors can help improve their care.
-
Hepatic Vein Filling Fraction vs TAPSE to Check Right Heart Function in Mechanically Ventilated ICU Patients
We’re testing if the hepatic vein systolic filling fraction can reliably show how well the right side of the heart is pumping in adults on breathing machines in the ICU.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.